drugset / Trial / NCT00170469
Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed
Phase 2
Completed
226 enrolled
PharmAthene UK Limited
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
This is a dose ranging study comparing different vaccine schedules of rPA vaccine, for Anthrax, to the licensed dose of AVA, another Anthrax vaccine. Safety and the capability to induce an immune response will be evaluated.
Timeline
- Start
- 2005-03
- Primary completion
- 2007-02
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | AVA | Vaccine | — | — |
| Subject | rPA vaccine | Vaccine | — | — |